TheraVida

Executive Summary

TheraVida is a clinical-stage specialty pharmaceutical company developing novel therapies for hyperhidrosis, a condition characterized by excessive sweating that significantly impacts quality of life. Its lead candidate, Anhydrix™, is an oral, systemic drug that has completed a Phase 2 trial for primary focal hyperhidrosis. The company's focus on improved tolerability, safety, and efficacy addresses a significant unmet need, as current treatments are often limited by side effects or insufficient efficacy. With a strong scientific foundation and a clear clinical path forward, TheraVida is well-positioned to advance Anhydrix into late-stage development and potentially capture a meaningful share of the hyperhidrosis market.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 Clinical Trial for Anhydrix70% success
• Q3 2026Presentation of Full Phase 2 Results at Major Medical Conference90% success
• Q2 2026FDA End-of-Phase 2 Meeting to Discuss Pivotal Trial Design85% success